Search Results 201-210 of 22532 for prostate cancer

1. S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer - Mayo Clinic

   The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation ...

2. Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer - Mayo Clinic

   ... prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells ...

3. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) - Mayo Clinic

   A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate ...

4. Mayo Clinic Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer

   Evaluating men for prostate cancer recurrence has long been a major challenge; physicians have had to wait until a patient's prostate-specific antigen (PSA) ...

5. Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer. Print details. Share; Facebook · Twitter. Overview; Participation eligibility ...

6. A Study to Identify Genetic Markers in Non-Cancerous Prostate Tissues, and Compare to Better Identify the Markers Unique to Prostate Cancer - Mayo Clinic

   ... prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.

7. 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) - Mayo Clinic

   The purpose of this study is to evaluate 64Cu-SAR-bisPSMA and 67Cu-ARbisPSMA administered to participants with metastatic castrate resistant prostate cancer ( ...

8. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer - Mayo Clinic

   This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of ...

9. Bone metastasis - Symptoms & causes - Mayo Clinic

   ... cancers most likely to cause bone metastasis include: Breast cancer; Kidney cancer; Lung cancer; Lymphoma; Multiple myeloma; Prostate cancer; Thyroid cancer.

10. Living With Cancer: Elevated prostate-specific antigen after partial prostate removal - Mayo Clinic News Network

    However, cancer is just one of several possible causes of increased prostate-specific antigen levels. After any procedure for an enlarged prostate, a number of ...